How xylazine affects opioid and sigma receptors
Xylazine Interaction with Opioid Receptors: Binding and Signaling
This work looks at whether xylazine and its breakdown products stick to and change human opioid and sigma receptors, which matters for people exposed to xylazine-laced street drugs.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11323119 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers will use lab cells that carry human opioid and sigma receptors to see where xylazine and its metabolites bind and how they change receptor signaling. They will measure binding strength and test if xylazine acts like an opioid, boosts opioid signals, or blocks other receptor activity using biochemical and cell-based assays. The team will also measure effects on cAMP signaling and use protein activity sensors to detail how xylazine changes receptor function. Findings will help explain why xylazine mixed into illicit drugs alters overdose and withdrawal responses.
Who could benefit from this research
Good fit: People exposed to xylazine through contaminated street drugs, people with opioid use disorder who have experienced xylazine-related effects, or those treated for suspected xylazine-involved overdose are the most directly relevant groups.
Not a fit: Patients without exposure to xylazine or those seeking immediate clinical treatment will not directly benefit from these laboratory findings in the short term.
Why it matters
Potential benefit: If successful, this work could clarify why xylazine worsens overdoses or causes unusual withdrawal and guide better emergency and treatment strategies.
How similar studies have performed: Prior lab and animal studies show xylazine binds sigma receptors and can cause naloxone-precipitated withdrawal in mice, but detailed actions at human opioid and sigma receptors remain incompletely described.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Bidlack, Jean M — University of Rochester
- Study coordinator: Bidlack, Jean M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.